Your shopping cart is currently empty

IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $54 | - | In Stock |
| Description | IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research. |
| In vitro | IRG1-IN-1 (0.5 mM; 1 mM) partially inhibits the proliferation of C-IRG1-9 rat glioma cells [1]. IRG1-IN-1 (0.5 mM; 2 mM) reduces the production of itaconic acid and the secretion of TNFα from human monocyte-derived macrophages (hMDMs) stimulated with LPS [1].IRG1-IN-1 (10μM) shows a decrease in trimethylation of histone 3 at lysine 4 (H3K4me3) in CR-activated hCD8+ T cells [1]. IRG1-IN-1 (10 nM) increases the proliferation of TCR-activated hCD8+ T cells [1]. |
| In vivo | IRG1-IN-1 administered intraperitoneally at a dose of 0.2 mg/kg for 27 days demonstrates a significant anti-tumor effect in C57BL/6 mice [1]. |
| Molecular Weight | 314.31 |
| Formula | C18H15FO4 |
| Cas No. | 2407652-42-8 |
| Smiles | O=C(O)C(=CC1=CC=C(F)C=C1)C(C(=O)O)CC=2C=CC=CC2 |
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (254.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.5 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.